华东医药：公司始终将创新作为核心战略，研发聚焦于具有差异化和临床价值的领域

Core Viewpoint - Huadong Medicine (000963) is focusing on innovative research and development, particularly in exploring different administration routes for HDM1005, including oral formulations, based on cutting-edge technology and patient needs [1] Group 1 - The company has initiated exploratory research on various administration routes for HDM1005, including oral dosage forms [1] - Early evaluations are currently underway, and progress will be disclosed in accordance with regulations [1] - Innovation remains a core strategy for the company, with R&D concentrated on areas that offer differentiation and clinical value [1]